APEH — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1616366	0.55	1/20
SCHEMBL11560494	0.55	1/20
SCHEMBL11560496	0.55	1/20
SCHEMBL16194668	0.50	1/20
SCHEMBL16194669	0.50	1/20
SCHEMBL16194670	0.50	1/20
SCHEMBL29713729	0.50	1/20
SCHEMBL3969689	0.48	1/20
SCHEMBL24282442	0.47	1/20
SCHEMBL19002422	0.47	1/20
SCHEMBL11562973	0.47	1/20
SCHEMBL11565751	0.47	1/20
SCHEMBL1599348	0.47	1/20
SCHEMBL28139909	0.47	1/20
SCHEMBL11562835	0.46	1/20
SCHEMBL1365701	0.46	1/20
SCHEMBL13847398	0.46	1/20
SCHEMBL11567151	0.45	1/20
SCHEMBL2457308	0.45	1/20
SCHEMBL11557463	0.44	1/20

Clinical trials — most relevant to APEH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Effectiveness of Vitamin D in Primary Dysmenorrhoea	PHASE3	COMPLETED
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)	PHASE1/PHASE2	RECRUITING
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors	PHASE1/PHASE2	COMPLETED
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects	PHASE1	COMPLETED
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects	PHASE1	COMPLETED
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer	PHASE1	COMPLETED
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects	PHASE1	COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL).	nan	RECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial	nan	COMPLETED
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines	nan	UNKNOWN
The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line	nan	UNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker	nan	UNKNOWN
Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases	nan	COMPLETED
Effect of NAC on Sleep Apnea	nan	UNKNOWN
Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a APEH binder may also engage these)

Protein	Name	Similarity
P25154	—	1.000	P25154 →
P13676	—	1.000	P13676 →
P80227	—	1.000	P80227 →
P19205	—	1.000	P19205 →
Q8R146	—	1.000	Q8R146 →
Q8BVG4	—	0.973	Q8BVG4 →
DPP9	Dipeptidyl peptidase 9	0.973	landscape →
A0A2R8QP51	—	0.966	A0A2R8QP51 →
P79106	—	0.963	P79106 →
Q14CH1	—	0.962	Q14CH1 →
P83006	—	0.962	P83006 →
Q5NVK5	—	0.961	Q5NVK5 →
Q0V8R7	—	0.961	Q0V8R7 →
Q8BYR1	—	0.960	Q8BYR1 →
Q9D2V7	—	0.959	Q9D2V7 →
Q8BNV1	—	0.959	Q8BNV1 →
Q05AM5	—	0.959	Q05AM5 →
Q9BV38	—	0.959	Q9BV38 →
Q8VDG7	—	0.958	Q8VDG7 →
Q3SZD4	—	0.958	Q3SZD4 →
Q96CB9	—	0.958	Q96CB9 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.957	landscape →
A0A1L8HX76	—	0.957	A0A1L8HX76 →
Q99J79	—	0.956	Q99J79 →
Q5RFM7	—	0.956	Q5RFM7 →
Q9UBK8	—	0.956	Q9UBK8 →
Q91YR5	—	0.956	Q91YR5 →
Q92089	—	0.955	Q92089 →
Q5U4D9	—	0.955	Q5U4D9 →
O08914	—	0.955	O08914 →